FY22 largely in-line; Auto/VR to accelerate growth
–Strong 3Q results on accelerating AI revenue
Accelerating growth in finished drug sales
Accelerating the financing of sustainable transport fuels
Recent correction overdone; Investment to accelerate “3+3 strategy” transition
3Q24 sales volume accelerated to +21% YoY; on track to achieve target
Bidding data implied accelerated software substitution
CMS Strategy Weekly (27 Feb 2023) US PCE inflation accelerated in January
The Diagnostic Financial Accelerator
Restructuring to focus on Gen AI business and accelerate breakeven progress